Use code FIRST5 5% off your first order
HomeAll Peptides
Weight LossHealing & RecoverySkin & Anti-AgingGH
GuidesCOAAboutContactMy ordersCart
Your specimens

Research cart

Your cart is empty

Browse Collection
← Back to catalogue
Retatrutide
Weight Loss

Retatrutide

Triple agonism. Unprecedented metabolic research leverage.

Novel triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon component adds thermogenic and lipolytic effects, representing a potential advancement over dual agonists.

₹3,199

Dispatched within 24 hours in cold-chain packaging · delivered in 2–4 days, every Indian pin code · free shipping.

Research dose
1 - 12mg weekly, subcutaneous
Molecular weight
~4400 g/mol
Sequence
Triple agonist (39 AA)
Category
Weight Loss
Third-party verified · Janoshik
Purity 99.790% · 10.13 mg
View Certificate of Analysis ↗

Common questions

How is this shipped?

All compounds ship cold-chain in an insulated pack with ice gel. Express courier, typically 2–4 days pan-India.

What is the storage protocol?

Store lyophilised powder at −20°C. After reconstituting with bacteriostatic water, store at 2–8°C and use within 28 days.

Is a Certificate of Analysis included?

Yes. A QR-linked COA showing HPLC purity trace, mass spec, and LAL endotoxin result from an ISO 17025-accredited lab ships with every vial.

What assays are run on each batch?

Reverse-phase C18 HPLC for purity and area%, ESI-MS for molecular weight confirmation, and LAL endotoxin screening.

Is this for human use?

No. All products are sold strictly for in-vitro laboratory research. Not intended for human or animal administration.

Selected literature

TRIUMPH-4 Phase 3 — Retatrutide delivered average 26.2% weight loss at 96 weeks
Dec 2025 · Lilly Investor Relations · TRIUMPH-4
TRIUMPH Programme Rationale and Trial Design
Oct 2025 · PubMed · PMID 41090431
Body Composition Substudy of Retatrutide Phase 2
Aug 2025 · PubMed · PMID 40609566
Retatrutide in Obesity: Systematic Review and Meta-Analysis
Jul 2025 · PubMed · PMID 40728138
Structural Insights into Triple Agonism of Retatrutide
2024 · Cell Research · doi:10.1038/s41421-024-00700-0
Retatrutide Phase 2 Dose-Finding — NEJM
2023 · New England Journal of Medicine · doi:10.1056/NEJMoa2301972
Delivery Proof

Real packages. Real researchers.

Photos sent by customers on WhatsApp, the day their order arrived.

Delivery photo shared by an AthenaBioLabs customer
Delivery photo shared by an AthenaBioLabs customer
Delivery photo shared by an AthenaBioLabs customer
Delivery photo shared by an AthenaBioLabs customer
See All Delivery Photos →

You may also research